STORY / PUBLIC SOURCE RECORD
Norway’s nuclear medicine imaging and diagnostics ecosystem
- Published 28 October 2025; updated 6 August 2026; estimated reading time 5 minutes.
- The article describes Norway’s radiopharmacy and radiodiagnostics expertise, including radiopharmaceuticals and radioisotopes used for medical imaging, and a national value chain spanning production, preclinical and clinical research, and dosimetry. It says Norwegian scientists have worked in nuclear medicine for more than 25 years.
- GE HealthCare Norway: the article describes activity across cyclotrons, radiopharmaceuticals, scanners, diagnostic software and dosimetry, and R&D partnerships with the Norwegian Medical Cyclotron Centre, University of Oslo and Oslo University Hospital. It reports that GE imaging agents are used in four patient procedures per second worldwide (attributed to Evy Stavik). It also describes collaboration with Japan and a 2025 visit to Nihon Medi-Physics.
- PET development: the article describes a public-private effort and says a 2004 Norwegian Parliament grant plus cost-sharing by the Research Council of Norway and Amersham Health/GE HealthCare enabled Norway’s first PET centre at Rikshospitalet-Radiumhospitalet, now part of Oslo University Hospital.
- Norwegian Medical Cyclotron Centre: identified as the only commercial PET-tracer supplier in Norway, supplying southern Norway for over 20 years with GE HealthCare. Founded in 2006, it became GE’s radioisotope contract manufacturer in 2017. The article reports double-digit growth since founding and a facility expansion intended to triple capacity/impact, including a second cyclotron and two clean rooms.
- Other capabilities: partnership with Alliance Medical for mobile/modular regional-hospital PET units; Oslo Imaging and Therapy Lab (OITL), a CRO for radiopharmaceutical development bridging preclinical and clinical work.
- Future work described: theranostics for targeted treatment guided by PET, and a project for large-scale enrichment of stable isotopes that can be irradiated to make medical isotopes currently in short global supply.
- Contact listed: Rasmus Malmborg, Investment Manager, Health and Life Science, Oslo; rasmus.malmborg@innovasjonnorge.no.
- Organizations and source details are reported as described in the article and may reflect the publication date; verify current status with the linked organizations.